Publications

Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.

Ghram M, Morris G, Culjkovic-Kraljacic B, Mars J-C, Gendron P, Skrabanek L, Revuelta MVictoria, Cerchietti L, Guzman ML, Borden KLB.  2023.  The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.. EMBO J. 42(7):e110496.

Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al..  2023.  Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.. Blood.

Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V et al..  2023.  Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.. Nat Med. 29(3):632-645.

Clauzure M, Delgado MATáquez, Phillip JM, Revuelta MV, Cerchietti L, Medina VA.  2022.  Histamine H4 Receptor Agonism Induces Antitumor Effects in Human T-Cell Lymphoma.. Int J Mol Sci. 23(3)

Cayrol F, Revuelta MV, Debernardi M, Paulazo A, Phillip JM, Zamponi N, Sterle H, Flaqué MCDíaz, Magro C, Marullo R et al..  2022.  Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.. Mol Cancer Ther. 21(9):1485-1496.

Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones J, Drew J, Wu C, Mulvey E et al..  2022.  Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.. Blood. 139(8):1147-1159.

Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, N Henry L, Dillon H, Little RF et al..  2022.  A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas . J Geriatr Oncol. 13(2):258-264.

Zaitsev A, Chelushkin M, Dyikanov D, Cheremushkin I, Shpak B, Nomie K, Zyrin V, Nuzhdina E, Lozinsky Y, Zotova A et al..  2022.  Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes.. Cancer Cell. 40(8):879-894.e16.

Li M, Teater MR, Hong JYoung, Park NR, Duy C, Shen H, Wang L, Chen Z, Cerchietti L, Davidson SM et al..  2022.  Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival.. Blood Cancer Discov. 3(1):50-65.

Gomari DP, Schweickart A, Cerchietti L, Paietta E, Fernandez H, Al-Amin H, Suhre K, Krumsiek J.  2022.  Variational autoencoders learn transferrable representations of metabolomics data.. Commun Biol. 5(1):645.

Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, Cacciapuoti MTeresa, Mensah AAdjeiwaa, Sartori G, Munz N et al..  2021.  Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.. Haematologica.

Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MTeresa, Antysheva Z, Svekolkin V, Tikhonova E, Miheecheva N, Kuzkina N et al..  2021.  Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures.. Cancer Discov.

Marullo R, Castro M, Yomtoubian S, M Calvo-Vidal N, Revuelta MVictoria, Krumsiek J, Cho A, Morgado PCresta, Yang SN, Medina V et al..  2021.  The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases.. Sci Adv. 7(45):eabg1964.

M Calvo-Vidal N, Zamponi N, Krumsiek J, Stockslager MA, Revuelta MV, Phillip JM, Marullo R, Tikhonova E, Kotlov N, Patel J et al..  2021.  Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.. Cancer Res. 81(20):5202-5216.

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E et al..  2020.  Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep. 30(3):755-770.e6.

McIntyre ABR, Gokhale NS, Cerchietti L, Jaffrey SR, Horner SM, Mason CE.  2020.  Limits in the detection of mA changes using MeRIP/mA-seq.. Sci Rep. 10(1):6590.

Fiore D, Cappelli LVincenzo, Zumbo P, Phillips JM, Liu Z, Cheng S, Yoffe L, Ghione P, Di Maggio F, Dogan A et al..  2020.  A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries.. Cancers (Basel). 12(6)

Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, Manni M, Tam W, Inghirami G, Elemento O et al..  2020.  Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.. Sci Rep. 10(1):13094.

Fernando TM, Marullo R, Gresely BPera, Phillip JM, Yang SNing, Lundell-Smith G, Torregroza I, Ahn H, Evans T, Gyorffy B et al..  2019.  BCL6 evolved to enable stress tolerance in vertebrates and is broadly required by cancer cells to adapt to stress.. Cancer Discov.

Li M, Chiang Y-L, Lyssiotis CA, Teater MR, Hong JYoung, Shen H, Wang L, Hu J, Jing H, Chen Z et al..  2019.  Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.. Cancer Cell. 35(6):916-931.e9.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.  2018.  The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^.. Leuk Lymphoma. 59(1):256-258.

Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MNieves et al..  2018.  Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.. Blood. 132(19):2016-2025.

Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.

Pera B, Krumsiek J, Assouline SE, Marullo R, Patel J, Phillip JM, Roman L, Mann KK, Cerchietti L.  2018.  Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.. EBioMedicine. 28:80-89.